Table 3.
Bivariate analysis
| Chemotherapy Toxicity | ||||
|---|---|---|---|---|
| Overall N=51 (%) | Normal baseline CA125 (n=15) | Abnormal baseline CA125 (n=36) | p value | |
| Grade 3–5 | 19 (37) | 2 (13) | 17 (47) | 0.03* |
| Heme | 11 (22) | 1 (7) | 10 (28) | 0.14 |
| Non-heme | 15 (30) | 1 (7) | 14 (39) | 0.04* |
| Hospitalization | 11 (22) | 2 (13) | 9 (25) | 0.47 |
| Dose reduction | 17 (33) | 1 (7) | 16 (44) | 0.01* |
| Dose delay | 18 (35) | 5 (33) | 13 (36) | 1.0 |
| Discontinuation of chemotherapy | 10 (20) | 1 (7) | 9 (25) | 0.25 |
| Geriatric Assessment | ||||
| Mean GA score | Mean GA score | |||
| Function (MOS physical) | 75.2 | 75.5 | 0.97 | |
| Function (IADL) | 13.7 | 12.9 | 0.05* | |
| Function (MD KPS) | 86.0 | 80.9 | 0.05* | |
| Function (Patient-rated KPS) | 88.7 | 86.9 | 0.59 | |
| Falls | 0.5 | 0.3 | 0.46 | |
| Timed Up and Go | 9.6 | 11.4 | 0.40 | |
| Psychological status (HADS) | 7.8 | 8.3 | 0.88 | |
| Social activity | 61.7 | 55.7 | 0.27 | |
| Social support | 88.9 | 86.3 | 0.38 | |
| No. of comorbidities | 3.1 | 2.2 | 0.49 | |
| No. of prescription medications | 4.7 | 4.1 | 0.76 | |
*
statistically significant
HADS= Hospital Anxiety and Depression Scale; IADL= Instrumental Activities of Daily Living; KPS= Karnofsky Performance Scale; MOS=Medical Outcomes Study